K
Kouichi Hashimoto
Researcher at Daiichi Sankyo
Publications - 7
Citations - 153
Kouichi Hashimoto is an academic researcher from Daiichi Sankyo. The author has contributed to research in topics: Nucleic acid & Luciferase. The author has an hindex of 3, co-authored 7 publications receiving 146 citations.
Papers
More filters
Journal ArticleDOI
Prolonged Targeting of Ischemic/Reperfused Myocardium by Liposomal Adenosine Augments Cardioprotection in Rats
Hiroyuki Takahama,Tetsuo Minamino,Hiroshi Asanuma,Masashi Fujita,Tomohiro Asai,Masakatsu Wakeno,Hideyuki Sasaki,Hiroshi Kikuchi,Kouichi Hashimoto,Naoto Oku,Masanori Asakura,Jiyoong Kim,Seiji Takashima,Kazuo Komamura,Masaru Sugimachi,Naoki Mochizuki,Masafumi Kitakaze +16 more
TL;DR: An infusion as PEGylated liposomes augmented the cardioprotective effects of adenosine against ischemia/reperfusion injury and reduced its unfavorable hemodynamic effects.
Journal ArticleDOI
In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP).
Kazutaka Atobe,Tatsuhiro Ishida,Emi Ishida,Kouichi Hashimoto,Hideo Kobayashi,Jyunko Yasuda,Takanori Aoki,Ken-ichi Obata,Hiroshi Kikuchi,Hidetaka Akita,Tomohiro Asai,Hideyoshi Harashima,Naoto Oku,Hiroshi Kiwada +13 more
TL;DR: It would be expected that DXR-SIL[anti-MT1-MMP(Fab')] may achieve direct tumor cell killing and indirect tumor cell kill via the destruction of the tumor endothelium in vivo, and this strategy may have the potential for overcoming some major limitations in conventional chemotherapy in vivo.
Journal ArticleDOI
Establishment of evaluation method for siRNA delivery using stable cell line carrying the luciferase reporter gene.
TL;DR: The reliable evaluation method for siRNA delivery in vitro was established by using NFAT reporter HeLa stable cell line or CHO (pMAM-luc) cell line that had DNA encoding luciferase, and it was considered that the cotransfection method should be avoided when the authors confirm RNAi efficiency.
Patent
Composition for introduction of nucleic acid
TL;DR: In this article, the authors presented a composition with weak cytotoxicity for introducing a nucleic acid, such as a short oligonucleotide or a gene, into a cell and expression of the gene in the cell with improved capability for introduction of the nucleic acids, and a novel compound contained in the composition.
Patent
Composition for nucleic-acid transfection
TL;DR: In this paper, a composition for the intracellular introduction of a nucleic acid was proposed, which was improved by using a compound represented by the following formula: (I) (wherein R1 and R2 are the same or different and each means a C12-22 (un)saturated hydrocarbon group; R3 means C1-6 alkyl or C 1-6 hydroxyalkyl; m means an integer of 1-10; and X means halogeno) and a phospholipid.